BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Liu L, Zhang CZ, Cai M, Fu J, Chen GG, Yun J. Downregulation of polo-like kinase 4 in hepatocellular carcinoma associates with poor prognosis. PLoS One 2012;7:e41293. [PMID: 22829937 DOI: 10.1371/journal.pone.0041293] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 3.4] [Reference Citation Analysis]
Number Citing Articles
1 Suri A, Bailey AW, Tavares MT, Gunosewoyo H, Dyer CP, Grupenmacher AT, Piper DR, Horton RA, Tomita T, Kozikowski AP, Roy SM, Sredni ST. Evaluation of Protein Kinase Inhibitors with PLK4 Cross-Over Potential in a Pre-Clinical Model of Cancer. Int J Mol Sci 2019;20:E2112. [PMID: 31035676 DOI: 10.3390/ijms20092112] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
2 Sampson PB, Liu Y, Forrest B, Cumming G, Li S, Patel NK, Edwards L, Laufer R, Feher M, Ban F, Awrey DE, Mao G, Plotnikova O, Hodgson R, Beletskaya I, Mason JM, Luo X, Nadeem V, Wei X, Kiarash R, Madeira B, Huang P, Mak TW, Pan G, Pauls HW. The Discovery of Polo-Like Kinase 4 Inhibitors: Identification of (1 R ,2 S )-2-(3-(( E )-4-((( cis )-2,6-Dimethylmorpholino)methyl)styryl)-1 H -indazol-6-yl)-5′-methoxyspiro[cyclopropane-1,3′-indolin]-2′-one (CFI-400945) as a Potent, Orally Active Antitumor Agent. J Med Chem 2015;58:147-69. [DOI: 10.1021/jm5005336] [Cited by in Crossref: 75] [Cited by in F6Publishing: 62] [Article Influence: 9.4] [Reference Citation Analysis]
3 Zhao Y, Wang X. PLK4: a promising target for cancer therapy. J Cancer Res Clin Oncol 2019;145:2413-22. [PMID: 31492983 DOI: 10.1007/s00432-019-02994-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
4 Zeng Y, Li N, Liu W, Zeng M, Cheng J, Huang J. Analyses of expressions and prognostic values of Polo-like kinases in non-small cell lung cancer. J Cancer Res Clin Oncol 2020;146:2447-60. [PMID: 32627077 DOI: 10.1007/s00432-020-03288-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Holland AJ, Fachinetti D, Zhu Q, Bauer M, Verma IM, Nigg EA, Cleveland DW. The autoregulated instability of Polo-like kinase 4 limits centrosome duplication to once per cell cycle. Genes Dev 2012;26:2684-9. [PMID: 23249732 DOI: 10.1101/gad.207027.112] [Cited by in Crossref: 96] [Cited by in F6Publishing: 92] [Article Influence: 10.7] [Reference Citation Analysis]
6 Wang Q, Zhao ZB, Wang G, Hui Z, Wang MH, Pan JF, Zheng H. High expression of KIF26B in breast cancer associates with poor prognosis. PLoS One 2013;8:e61640. [PMID: 23585914 DOI: 10.1371/journal.pone.0061640] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 2.9] [Reference Citation Analysis]
7 Maniswami RR, Prashanth S, Karanth AV, Koushik S, Govindaraj H, Mullangi R, Rajagopal S, Jegatheesan SK. PLK4: a link between centriole biogenesis and cancer. Expert Opin Ther Targets 2018;22:59-73. [PMID: 29171762 DOI: 10.1080/14728222.2018.1410140] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
8 Kim TY, Jackson S, Xiong Y, Whitsett TG, Lobello JR, Weiss GJ, Tran NL, Bang YJ, Der CJ. CRL4A-FBXW5-mediated degradation of DLC1 Rho GTPase-activating protein tumor suppressor promotes non-small cell lung cancer cell growth. Proc Natl Acad Sci U S A 2013;110:16868-73. [PMID: 24082123 DOI: 10.1073/pnas.1306358110] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 4.6] [Reference Citation Analysis]
9 Zhang YM, Liu ZR, Cui ZL, Yang C, Yang L, Li Y, Shen ZY. Interleukin-22 contributes to liver regeneration in mice with concanavalin A-induced hepatitis after hepatectomy. World J Gastroenterol 2016; 22(6): 2081-2091 [PMID: 26877612 DOI: 10.3748/wjg.v22.i6.2081] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
10 Leoni A, Locatelli A, Morigi R, Rambaldi M. 2-Indolinone a versatile scaffold for treatment of cancer: a patent review (2008-2014). Expert Opin Ther Pat 2016;26:149-73. [PMID: 26561198 DOI: 10.1517/13543776.2016.1118059] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.9] [Reference Citation Analysis]
11 Yang F, Deng R, Qian XJ, Chang SH, Wu XQ, Qin J, Feng GK, Ding K, Zhu XF. Feedback loops blockade potentiates apoptosis induction and antitumor activity of a novel AKT inhibitor DC120 in human liver cancer. Cell Death Dis 2014;5:e1114. [PMID: 24625973 DOI: 10.1038/cddis.2014.43] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
12 Miyamoto T, Bando Y, Koh E, Tsujimura A, Miyagawa Y, Iijima M, Namiki M, Shiina M, Ogata K, Matsumoto N, Sengoku K. A PLK4 mutation causing azoospermia in a man with Sertoli cell-only syndrome. Andrology 2016;4:75-81. [PMID: 26452337 DOI: 10.1111/andr.12113] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
13 Lambrus BG, Uetake Y, Clutario KM, Daggubati V, Snyder M, Sluder G, Holland AJ. p53 protects against genome instability following centriole duplication failure. J Cell Biol 2015;210:63-77. [PMID: 26150389 DOI: 10.1083/jcb.201502089] [Cited by in Crossref: 104] [Cited by in F6Publishing: 85] [Article Influence: 14.9] [Reference Citation Analysis]
14 Mason JM, Lin DC, Wei X, Che Y, Yao Y, Kiarash R, Cescon DW, Fletcher GC, Awrey DE, Bray MR, Pan G, Mak TW. Functional characterization of CFI-400945, a Polo-like kinase 4 inhibitor, as a potential anticancer agent. Cancer Cell. 2014;26:163-176. [PMID: 25043604 DOI: 10.1016/j.ccr.2014.05.006] [Cited by in Crossref: 112] [Cited by in F6Publishing: 99] [Article Influence: 14.0] [Reference Citation Analysis]
15 Sredni ST, Suzuki M, Yang JP, Topczewski J, Bailey AW, Gokirmak T, Gross JN, de Andrade A, Kondo A, Piper DR, Tomita T. A functional screening of the kinome identifies the Polo-like kinase 4 as a potential therapeutic target for malignant rhabdoid tumors, and possibly, other embryonal tumors of the brain. Pediatr Blood Cancer 2017;64. [PMID: 28398638 DOI: 10.1002/pbc.26551] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
16 Shinmura K, Kurabe N, Goto M, Yamada H, Natsume H, Konno H, Sugimura H. PLK4 overexpression and its effect on centrosome regulation and chromosome stability in human gastric cancer. Mol Biol Rep. 2014;41:6635-6644. [PMID: 24981932 DOI: 10.1007/s11033-014-3546-2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]
17 Ward A, Hudson JW. p53-Dependent and cell specific epigenetic regulation of the polo-like kinases under oxidative stress. PLoS One 2014;9:e87918. [PMID: 24498222 DOI: 10.1371/journal.pone.0087918] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
18 Bao J, Yu Y, Chen J, He Y, Chen X, Ren Z, Xue C, Liu L, Hu Q, Li J, Cui G, Sun R. MiR-126 negatively regulates PLK-4 to impact the development of hepatocellular carcinoma via ATR/CHEK1 pathway. Cell Death Dis 2018;9:1045. [PMID: 30315225 DOI: 10.1038/s41419-018-1020-0] [Cited by in Crossref: 36] [Cited by in F6Publishing: 43] [Article Influence: 9.0] [Reference Citation Analysis]
19 Fu J, Qiu H, Cai M, Pan Y, Cao Y, Liu L, Yun J, Zhang CZ. Low cyclin F expression in hepatocellular carcinoma associates with poor differentiation and unfavorable prognosis. Cancer Sci 2013;104:508-15. [PMID: 23305207 DOI: 10.1111/cas.12100] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 3.7] [Reference Citation Analysis]
20 Nam HJ, Naylor RM, van Deursen JM. Centrosome dynamics as a source of chromosomal instability. Trends Cell Biol 2015;25:65-73. [PMID: 25455111 DOI: 10.1016/j.tcb.2014.10.002] [Cited by in Crossref: 52] [Cited by in F6Publishing: 49] [Article Influence: 6.5] [Reference Citation Analysis]
21 Fan G, Sun L, Shan P, Zhang X, Huan J, Zhang X, Li D, Wang T, Wei T, Zhang X, Gu X, Yao L, Xuan Y, Hou Z, Cui Y, Cao L, Li X, Zhang S, Wang C. Loss of KLF14 triggers centrosome amplification and tumorigenesis. Nat Commun 2015;6:8450. [PMID: 26439168 DOI: 10.1038/ncomms9450] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 6.1] [Reference Citation Analysis]
22 Miao X, Chen Y, Xu S, Zhao T, Liu J, Li Y, Wang J, Zhang J, Guo G. TCTP overexpression is associated with the development and progression of glioma. Tumor Biol 2013;34:3357-61. [DOI: 10.1007/s13277-013-0906-9] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 3.2] [Reference Citation Analysis]
23 Kratz AS, Bärenz F, Richter KT, Hoffmann I. Plk4-dependent phosphorylation of STIL is required for centriole duplication. Biol Open 2015;4:370-7. [PMID: 25701666 DOI: 10.1242/bio.201411023] [Cited by in Crossref: 86] [Cited by in F6Publishing: 75] [Article Influence: 12.3] [Reference Citation Analysis]
24 Zhang X, Wei C, Liang H, Han L. Polo-Like Kinase 4's Critical Role in Cancer Development and Strategies for Plk4-Targeted Therapy. Front Oncol 2021;11:587554. [PMID: 33777739 DOI: 10.3389/fonc.2021.587554] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
25 Xie XL, Zhu HX, Li YM, Chen DT, Fan TY. Differential expression of AURKA/PLK4 in quiescence and senescence of osteosarcoma U2OS cells. Cell Cycle 2020;19:884-94. [PMID: 32200684 DOI: 10.1080/15384101.2020.1731054] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Abreu P, Ivanics T, Jiang K, Chen K, E Hansen B, Sapisochin G, Ghanekar A. Novel biomarker for hepatocellular carcinoma: high tumoral PLK-4 expression is associated with better prognosis in patients without microvascular invasion. HPB (Oxford) 2021;23:359-66. [PMID: 32800449 DOI: 10.1016/j.hpb.2020.07.003] [Reference Citation Analysis]
27 Zhang Q, Li G, Zhang L, Sun X, Zhang D, Lu J, Ma J, Yan J, Chen ZJ. Maternal common variant rs2305957 spanning PLK4 is associated with blastocyst formation and early recurrent miscarriage. Fertil Steril 2017;107:1034-1040.e5. [PMID: 28238495 DOI: 10.1016/j.fertnstert.2017.01.006] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
28 Zhou Q, Fan G, Dong Y. Polo-like kinase 4 correlates with greater tumor size, lymph node metastasis and confers poor survival in non-small cell lung cancer. J Clin Lab Anal 2020;34:e23152. [PMID: 31876063 DOI: 10.1002/jcla.23152] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
29 Miyamoto T, Minase G, Shin T, Ueda H, Okada H, Sengoku K. Human male infertility and its genetic causes. Reprod Med Biol 2017;16:81-8. [PMID: 29259455 DOI: 10.1002/rmb2.12017] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 6.2] [Reference Citation Analysis]
30 Bose A, Dalal SN. Centrosome Amplification and Tumorigenesis: Cause or Effect? In: Kloc M, editor. The Golgi Apparatus and Centriole. Cham: Springer International Publishing; 2019. pp. 413-40. [DOI: 10.1007/978-3-030-23173-6_18] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
31 He Y, Wang H, Yan M, Yang X, Shen R, Ni X, Chen X, Yang P, Chen M, Lu X, Shao G, Zhou X, Shao Q. High LIN28A and PLK4 co‑expression is associated with poor prognosis in epithelial ovarian cancer. Mol Med Rep 2018;18:5327-36. [PMID: 30365085 DOI: 10.3892/mmr.2018.9562] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
32 Luo R, Zhang M, Liu L, Lu S, Zhang CZ, Yun J. Decrease of fibulin-3 in hepatocellular carcinoma indicates poor prognosis. PLoS One 2013;8:e70511. [PMID: 23936443 DOI: 10.1371/journal.pone.0070511] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]